An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report

• Main Authors: Ayako Chida-Nagai (Author), Takao Tsujioka (Author), Daisuke Sasaki (Author), Gaku Izumi (Author), Hirokuni Yamazawa (Author), Atsuhito Takeda (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Idiopathic pulmonary arterial hypertension (PAH) is a rare, progressive disease affecting the pulmonary arteries. Epoprostenol, a synthetic prostaglandin analog, is the most potent pharmacological treatment modality used in patients with PAH. However, it requires continuous intravenous infusion, whi...